Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model

doi:10.12998/wjcc.v13.i23.101742

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 23

This Article

(98)

(94)

(0)

(2498)

(4)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Aug 16, 2025; 13(23): 101742
Published online Aug 16, 2025. doi: 10.12998/wjcc.v13.i23.101742

Full Size Figure Download Figure

Figure 6 Decision curve analysis. The results of the decision curve analysis revealed that the net clinical benefit of the combined model was greater than that of the clinical model at all threshold probabilities between 0.16 and 0.76.

Citation: Zhao KF, Xie CB, Wu Y. Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model. World J Clin Cases 2025; 13(23): 101742
URL: https://www.wjgnet.com/2307-8960/full/v13/i23/101742.htm
DOI: https://dx.doi.org/10.12998/wjcc.v13.i23.101742

Zhao KF, Xie CB, Wu Y. Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model. World J Clin Cases 2025; 13(23): 101742 [PMID: 40821408 DOI: 10.12998/wjcc.v13.i23.101742]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.